Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Human-induced pluripotent stem cell-derived cardiomyocytes exhibit temporal changes in phenotype.

Ivashchenko CY, Pipes GC, Lozinskaya IM, Lin Z, Xiaoping X, Needle S, Grygielko ET, Hu E, Toomey JR, Lepore JJ, Willette RN.

Am J Physiol Heart Circ Physiol. 2013 Sep 15;305(6):H913-22. doi: 10.1152/ajpheart.00819.2012. Epub 2013 Jul 5.

2.

An orally active TRPV4 channel blocker prevents and resolves pulmonary edema induced by heart failure.

Thorneloe KS, Cheung M, Bao W, Alsaid H, Lenhard S, Jian MY, Costell M, Maniscalco-Hauk K, Krawiec JA, Olzinski A, Gordon E, Lozinskaya I, Elefante L, Qin P, Matasic DS, James C, Tunstead J, Donovan B, Kallal L, Waszkiewicz A, Vaidya K, Davenport EA, Larkin J, Burgert M, Casillas LN, Marquis RW, Ye G, Eidam HS, Goodman KB, Toomey JR, Roethke TJ, Jucker BM, Schnackenberg CG, Townsley MI, Lepore JJ, Willette RN.

Sci Transl Med. 2012 Nov 7;4(159):159ra148. doi: 10.1126/scitranslmed.3004276.

3.

The discovery of potent and long-acting oral factor Xa inhibitors with tetrahydroisoquinoline and benzazepine P4 motifs.

Watson NS, Adams C, Belton D, Brown D, Burns-Kurtis CL, Chaudry L, Chan C, Convery MA, Davies DE, Exall AM, Harling JD, Irvine S, Irving WR, Kleanthous S, McLay IM, Pateman AJ, Patikis AN, Roethke TJ, Senger S, Stelman GJ, Toomey JR, West RI, Whittaker C, Zhou P, Young RJ.

Bioorg Med Chem Lett. 2011 Mar 15;21(6):1588-92. doi: 10.1016/j.bmcl.2011.01.129. Epub 2011 Feb 2.

PMID:
21349711
4.

Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with aminoindane and phenylpyrrolidine P4 motifs.

Young RJ, Adams C, Blows M, Brown D, Burns-Kurtis CL, Chan C, Chaudry L, Convery MA, Davies DE, Exall AM, Foster G, Harling JD, Hortense E, Irvine S, Irving WR, Jackson S, Kleanthous S, Pateman AJ, Patikis AN, Roethka TJ, Senger S, Stelman GJ, Toomey JR, West RI, Whittaker C, Zhou P, Watson NS.

Bioorg Med Chem Lett. 2011 Mar 15;21(6):1582-7. doi: 10.1016/j.bmcl.2011.01.131. Epub 2011 Feb 1.

PMID:
21349710
5.

Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with monoaryl P4 motifs.

Kleanthous S, Borthwick AD, Brown D, Burns-Kurtis CL, Campbell M, Chaudry L, Chan C, Clarte MO, Convery MA, Harling JD, Hortense E, Irving WR, Irvine S, Pateman AJ, Patikis AN, Pinto IL, Pollard DR, Roethka TJ, Senger S, Shah GP, Stelman GJ, Toomey JR, Watson NS, West RI, Whittaker C, Zhou P, Young RJ.

Bioorg Med Chem Lett. 2010 Jan 15;20(2):618-22. doi: 10.1016/j.bmcl.2009.11.077. Epub 2009 Nov 20.

PMID:
20006499
6.

Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function.

Erhardt JA, Erickson-Miller CL, Aivado M, Abboud M, Pillarisetti K, Toomey JR.

Exp Hematol. 2009 Sep;37(9):1030-7. doi: 10.1016/j.exphem.2009.06.011. Epub 2009 Jul 24.

PMID:
19631713
7.

Antithrombotic potential of GW813893: a novel, orally active, active-site directed factor Xa inhibitor.

Abboud MA, Needle SJ, Burns-Kurtis CL, Valocik RE, Koster PF, Amour AJ, Chan C, Brown D, Chaudry L, Zhou P, Patikis A, Patel C, Pateman AJ, Young RJ, Watson NS, Toomey JR.

J Cardiovasc Pharmacol. 2008 Jul;52(1):66-71. doi: 10.1097/FJC.0b013e31817e9b9e.

PMID:
18645410
8.

Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with biaryl P4 motifs.

Young RJ, Borthwick AD, Brown D, Burns-Kurtis CL, Campbell M, Chan C, Charbaut M, Chung CW, Convery MA, Kelly HA, Paul King N, Kleanthous S, Mason AM, Pateman AJ, Patikis AN, Pinto IL, Pollard DR, Senger S, Shah GP, Toomey JR, Watson NS, Weston HE.

Bioorg Med Chem Lett. 2008 Jan 1;18(1):23-7. Epub 2007 Nov 17.

PMID:
18054228
9.

Structure and property based design of factor Xa inhibitors: biaryl pyrrolidin-2-ones incorporating basic heterocyclic motifs.

Young RJ, Borthwick AD, Brown D, Burns-Kurtis CL, Campbell M, Chan C, Charbaut M, Convery MA, Diallo H, Hortense E, Irving WR, Kelly HA, King NP, Kleanthous S, Mason AM, Pateman AJ, Patikis AN, Pinto IL, Pollard DR, Senger S, Shah GP, Toomey JR, Watson NS, Weston HE, Zhou P.

Bioorg Med Chem Lett. 2008 Jan 1;18(1):28-33. Epub 2007 Nov 13.

PMID:
18053714
10.

The quest for Factor VIIa exosite inhibitors.

Amour A, Hutchinson J, Ruiz AvendaƱo AM, Ratcliffe S, Alvarez E, Martin J, Toomey JR, Senger S, Wolfendale M, Mooney C.

Biochem Soc Trans. 2007 Jun;35(Pt 3):555-8.

PMID:
17511650
11.

Selective and dual action orally active inhibitors of thrombin and factor Xa.

Young RJ, Brown D, Burns-Kurtis CL, Chan C, Convery MA, Hubbard JA, Kelly HA, Pateman AJ, Patikis A, Senger S, Shah GP, Toomey JR, Watson NS, Zhou P.

Bioorg Med Chem Lett. 2007 May 15;17(10):2927-30. Epub 2007 Mar 30.

PMID:
17420122
12.

Factor Xa inhibitors: S1 binding interactions of a series of N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}sulfonamides.

Chan C, Borthwick AD, Brown D, Burns-Kurtis CL, Campbell M, Chaudry L, Chung CW, Convery MA, Hamblin JN, Johnstone L, Kelly HA, Kleanthous S, Patikis A, Patel C, Pateman AJ, Senger S, Shah GP, Toomey JR, Watson NS, Weston HE, Whitworth C, Young RJ, Zhou P.

J Med Chem. 2007 Apr 5;50(7):1546-57. Epub 2007 Mar 6.

PMID:
17338508
13.

A comparison of the beta-D-xyloside, odiparcil, to warfarin in a rat model of venous thrombosis.

Toomey JR, Abboud MA, Valocik RE, Koster PF, Burns-Kurtis CL, Pillarisetti K, Danoff TM, Erhardt JA.

J Thromb Haemost. 2006 Sep;4(9):1989-96.

14.

P2X1 stimulation promotes thrombin receptor-mediated platelet aggregation.

Erhardt JA, Toomey JR, Douglas SA, Johns DG.

J Thromb Haemost. 2006 Apr;4(4):882-90.

15.

Severe factor XI deficiency caused by a Gly555 to Glu mutation (factor XI-Glu555): a cross-reactive material positive variant defective in factor IX activation.

Zivelin A, Ogawa T, Bulvik S, Landau M, Toomey JR, Lane J, Seligsohn U, Gailani D.

J Thromb Haemost. 2004 Oct;2(10):1782-9.

16.

Potentiation of platelet activation through the stimulation of P2X1 receptors.

Erhardt JA, Pillarisetti K, Toomey JR.

J Thromb Haemost. 2003 Dec;1(12):2626-35.

17.

The antithrombotic efficacy of lotrafiban (SB 214857) in canine models of acute coronary thrombosis.

Toomey JR, Samanen J, Valocik RE, Koster PF, Barone FC, Willette RN.

Curr Drug Targets Cardiovasc Haematol Disord. 2002 Jun;2(1):13-25.

PMID:
12769654
18.

The factor IX gamma-carboxyglutamic acid (Gla) domain is involved in interactions between factor IX and factor XIa.

Aktimur A, Gabriel MA, Gailani D, Toomey JR.

J Biol Chem. 2003 Mar 7;278(10):7981-7. Epub 2002 Dec 20.

19.

Inhibition of factor IX(a) is protective in a rat model of thromboembolic stroke.

Toomey JR, Valocik RE, Koster PF, Gabriel MA, McVey M, Hart TK, Ohlstein EH, Parsons AA, Barone FC.

Stroke. 2002 Feb;33(2):578-85.

PMID:
11823673
20.

Activation of caspase-3/caspase-3-like activity in rat cardiomyocytes by an RGD peptide, but not the GPIIb/IIIa antagonist lotrafiban.

Erhardt JA, Ohlstein EH, Toomey JR, Gabriel MA, Willette RN, Yue TL, Barone FC, Parsons AA.

Thromb Res. 2001 Jul 15;103(2):143-8. No abstract available.

PMID:
11457472
21.
22.

An inhibitory anti-factor IX antibody effectively reduces thrombus formation in a rat model of venous thrombosis.

Feuerstein GZ, Toomey JR, Valocik R, Koster P, Patel A, Blackburn MN.

Thromb Haemost. 1999 Nov;82(5):1443-5.

PMID:
10595635
23.

Antithrombotic efficacy of a novel murine antihuman factor IX antibody in rats.

Feuerstein GZ, Patel A, Toomey JR, Bugelski P, Nichols AJ, Church WR, Valocik R, Koster P, Baker A, Blackburn MN.

Arterioscler Thromb Vasc Biol. 1999 Oct;19(10):2554-62.

PMID:
10521387
24.

Effect of tissue factor deficiency on mouse and tumor development.

Toomey JR, Kratzer KE, Lasky NM, Broze GJ Jr.

Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6922-6.

25.

Targeted disruption of the murine tissue factor gene results in embryonic lethality.

Toomey JR, Kratzer KE, Lasky NM, Stanton JJ, Broze GJ Jr.

Blood. 1996 Sep 1;88(5):1583-7.

26.

Receptor-mediated endocytosis of coagulation factor Xa requires cell surface-bound tissue factor pathway inhibitor.

Ho G, Toomey JR, Broze GJ Jr, Schwartz AL.

J Biol Chem. 1996 Apr 19;271(16):9497-502.

27.

The endothelial cell binding determinant of human factor IX resides in the gamma-carboxyglutamic acid domain.

Toomey JR, Smith KJ, Roberts HR, Stafford DW.

Biochemistry. 1992 Feb 18;31(6):1806-8.

PMID:
1310619
28.

Localization of the human tissue factor recognition determinant of human factor VIIa.

Toomey JR, Smith KJ, Stafford DW.

J Biol Chem. 1991 Oct 15;266(29):19198-202.

29.

Epitope localization of anti-factor VIII monoclonal antibodies determined by recombinant peptides.

Ware J, Toomey JR, Stafford DW.

Thromb Haemost. 1989 Apr 25;61(2):225-9.

PMID:
2473538
30.

Supplemental Content

Loading ...
Support Center